SGD-1882

Cat. No.:	HY-101127
CAS No.:	1222490-34-7
Molecular Formula:	$C_{42}H_{39}N_5O_7$
Molecular Weight:	725.79
Target:	ADC Cytotoxin
Pathway:	Antibody-drug Conjugate/ADC Related
Storage:	Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (137.78 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	1.3778 mL	6.8890 mL	13.7781 mL
	5 mM	0.2756 mL	1.3778 mL	2.7556 mL
	10 mM	0.1378 mL	0.6889 mL	1.3778 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

SGD-1882 is a cytotoxic, DNA minor-groove crosslinking agent pyrrolobenzodiazepine (PBD) dimer, acting as the payload for ADCs.

In Vitro

SGD-1882 is the cytotoxic payload undergoing clinical evaluation for anti-CD33 and anti-CD70 conjugates[1]. SGD-1882 is not an MDR1 substrate, and SGN-CD33A is conjugated to the SGD-1882. SGN-CD33A can kill MDR1 expressing CD33 positive AML patient samples and is currently in Phase I[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Eunhee G. Kim, et al. Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics. Biomol Ther (Seoul). 2015 Nov; 23(6): 493-509.

[2]. Dowdy Jackson, et al. Using the Lessons Learned From the Clinic to Improve the Preclinical Development of Antibody Drug Conjugates. Pharm Res. 2015; 32(11): 3458-3469.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA